Kidney Cancer Drugs Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Kidney Cancer Drugs Market to 2027 - Global Analysis and Forecasts By Therapeutic Class ( Targeted Therapy, Immunotherapy ); Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2) ) and Geography

Report Code: TIPRE00003834 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Kidney cancer refers to the cancer that initiates in the kidneys. The most common type of kidney cancer is the renal cell carcinoma that usually grows as a single tumor within a kidney. The other types of kidney cancer includes transitional cell carcinoma, Wilms tumor (nephroblastoma), renal sarcoma, renal adenomas, oncocytoma and others.

MARKET DYNAMICS
The kidney cancer drugs market is anticipated to grow in the forecast, owing to the factors such as increasing research and development leading to novel drugs in the market, robust pipeline for kidney cancer drugs and rising incidence of kidney cancer. In addition, rising awareness among patients for the availability of effective medication is likely to offer growth opportunities in the market.

MARKET SCOPE
The "Global Kidney Cancer Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of kidney cancer drugs market with detailed market segmentation therapeutic class, pharmacologic class and geography. The global kidney cancer drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading kidney cancer drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global kidney cancer drugs market is segmented on the basis of therapeutic class, pharmacologic class and geography. Based on therapeutic class, the market is segmented into targeted therapy and immunotherapy. Based on pharmacologic class, the global kidney cancer drugs market is segmented into angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (IL-2).
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global kidney cancer drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The kidney cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting kidney cancer drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the kidney cancer drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the kidney cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from kidney cancer drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for kidney cancer drugs market in the global market. Below mentioned is the list of few companies engaged in the kidney cancer drugs market.

The report also includes the profiles of key kidney cancer drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • Genentech, Inc.
  • Bristol-Myers Squibb Company
  • Exelixis, Inc.
  • Eisai Co., Ltd.
  • Prometheus Laboratories Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann La Roche Ltd.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Kidney Cancer Drugs Market - By Therapeutic Class
1.3.2 Kidney Cancer Drugs Market - By Pharmacologic Class
1.3.3 Kidney Cancer Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. KIDNEY CANCER DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. KIDNEY CANCER DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. KIDNEY CANCER DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. KIDNEY CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. KIDNEY CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. KIDNEY CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC CLASS
7.1. OVERVIEW
7.2. THERAPEUTIC CLASS MARKET FORECASTS AND ANALYSIS
7.3. TARGETED THERAPY
7.3.1. Overview
7.3.2. Targeted Therapy Market Forecast and Analysis
7.4. IMMUNOTHERAPY
7.4.1. Overview
7.4.2. Immunotherapy Market Forecast and Analysis
8. KIDNEY CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - PHARMACOLOGIC CLASS
8.1. OVERVIEW
8.2. PHARMACOLOGIC CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANGIOGENESIS INHIBITORS
8.3.1. Overview
8.3.2. Angiogenesis Inhibitors Market Forecast and Analysis
8.4. MTOR INHIBITORS
8.4.1. Overview
8.4.2. mTOR Inhibitors Market Forecast and Analysis
8.5. MONOCLONAL ANTIBODIES
8.5.1. Overview
8.5.2. Monoclonal Antibodies Market Forecast and Analysis
8.6. CYTOKINE IMMUNOTHERAPY (IL-2)
8.6.1. Overview
8.6.2. Cytokine Immunotherapy (IL-2) Market Forecast and Analysis
9. KIDNEY CANCER DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Kidney Cancer Drugs Market Overview
9.1.2 North America Kidney Cancer Drugs Market Forecasts and Analysis
9.1.3 North America Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.1.4 North America Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.1.5 North America Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Kidney Cancer Drugs Market
9.1.5.1.1 United States Kidney Cancer Drugs Market by Therapeutic Class
9.1.5.1.2 United States Kidney Cancer Drugs Market by Pharmacologic Class
9.1.5.2 Canada Kidney Cancer Drugs Market
9.1.5.2.1 Canada Kidney Cancer Drugs Market by Therapeutic Class
9.1.5.2.2 Canada Kidney Cancer Drugs Market by Pharmacologic Class
9.1.5.3 Mexico Kidney Cancer Drugs Market
9.1.5.3.1 Mexico Kidney Cancer Drugs Market by Therapeutic Class
9.1.5.3.2 Mexico Kidney Cancer Drugs Market by Pharmacologic Class
9.2. EUROPE
9.2.1 Europe Kidney Cancer Drugs Market Overview
9.2.2 Europe Kidney Cancer Drugs Market Forecasts and Analysis
9.2.3 Europe Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.2.4 Europe Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.2.5 Europe Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Kidney Cancer Drugs Market
9.2.5.1.1 Germany Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.1.2 Germany Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.2 France Kidney Cancer Drugs Market
9.2.5.2.1 France Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.2.2 France Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.3 Italy Kidney Cancer Drugs Market
9.2.5.3.1 Italy Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.3.2 Italy Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.4 Spain Kidney Cancer Drugs Market
9.2.5.4.1 Spain Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.4.2 Spain Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.5 United Kingdom Kidney Cancer Drugs Market
9.2.5.5.1 United Kingdom Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.5.2 United Kingdom Kidney Cancer Drugs Market by Pharmacologic Class
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Kidney Cancer Drugs Market Overview
9.3.2 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.3.4 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.3.5 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Kidney Cancer Drugs Market
9.3.5.1.1 Australia Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.1.2 Australia Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.2 China Kidney Cancer Drugs Market
9.3.5.2.1 China Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.2.2 China Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.3 India Kidney Cancer Drugs Market
9.3.5.3.1 India Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.3.2 India Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.4 Japan Kidney Cancer Drugs Market
9.3.5.4.1 Japan Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.4.2 Japan Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.5 South Korea Kidney Cancer Drugs Market
9.3.5.5.1 South Korea Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.5.2 South Korea Kidney Cancer Drugs Market by Pharmacologic Class
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Kidney Cancer Drugs Market Overview
9.4.2 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.4.4 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.4.5 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Kidney Cancer Drugs Market
9.4.5.1.1 South Africa Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.1.2 South Africa Kidney Cancer Drugs Market by Pharmacologic Class
9.4.5.2 Saudi Arabia Kidney Cancer Drugs Market
9.4.5.2.1 Saudi Arabia Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.2.2 Saudi Arabia Kidney Cancer Drugs Market by Pharmacologic Class
9.4.5.3 U.A.E Kidney Cancer Drugs Market
9.4.5.3.1 U.A.E Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.3.2 U.A.E Kidney Cancer Drugs Market by Pharmacologic Class
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Kidney Cancer Drugs Market Overview
9.5.2 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis
9.5.3 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.5.4 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.5.5 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Kidney Cancer Drugs Market
9.5.5.1.1 Brazil Kidney Cancer Drugs Market by Therapeutic Class
9.5.5.1.2 Brazil Kidney Cancer Drugs Market by Pharmacologic Class
9.5.5.2 Argentina Kidney Cancer Drugs Market
9.5.5.2.1 Argentina Kidney Cancer Drugs Market by Therapeutic Class
9.5.5.2.2 Argentina Kidney Cancer Drugs Market by Pharmacologic Class
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. KIDNEY CANCER DRUGS MARKET, KEY COMPANY PROFILES
11.1. PFIZER INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NOVARTIS AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BAYER AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GENENTECH, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB COMPANY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. EXELIXIS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. EISAI CO., LTD.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PROMETHEUS LABORATORIES INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GLAXOSMITHKLINE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. F. HOFFMANN LA ROCHE LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Pfizer Inc.
2. Novartis AG
3. Bayer AG
4. Genentech, Inc.
5. Bristol-Myers Squibb Company
6. Exelixis, Inc.
7. Eisai Co. , Ltd.
8. Prometheus Laboratories Inc.
9. GlaxoSmithKline plc
10. F. Hoffmann La Roche Ltd.